ANGPTL3 and atherosclerosis: Pharmacologic antagonism of ANGPTL3 with a human monoclonal antibody was found to greatly diminish plasma lipid levels and atherosclerosis, which is comparable to that reported previously in the same mouse model treated with atorvastatin [64].